Crearene AG

Dear business partners and friends around the world, I am grateful for a very successful year that Crearene has had despite all the global turmoil and crises. May all of you be safe and may all of continue to be optimistic and "future-building" as we are heading into a super-dynamic 2025. All the best and season's greetings, Frank Heideloff

A look back on 2024 – message from the CEO of Crearene AG   Looking back on a turbulent 2024 which globally was so full of crisis, only one word comes to my mind when I think about how the year has gone for Crearene: gratitude!   Our team at Crearene AG is grateful for the fabulous work of the UMCG team headed by Stephan Bakker who completed a clinical study demonstrating how creatine levels in depleted dialysis patients can be increased by embedding creatine in the dialysis process. Based on study results, we filed three new patents. We are grateful for the steps we are taking with Vietnamese market leading dialysis firm Bidiphar - Dược Bình Định in establishing a product partnership and we are equally happy about the co-operation with German start-up Renephro in their efforts for bringing personalized dialysis treatment options to the market via an innovative multi-chamber machine. Our long-term shareholders backed the company by a financing round in the summer, completing the whole process within only a matter of weeks. A big shoutout!  And of course, we are highly grateful for the co-operation with our long-term partner Alzchem Group AG, the world’s leading maker of high-quality creatine. What a year full of achievements!   And we will not rest in 2025 either. As we enter an exciting phase of product development and licensing our IP to partners in dialysis, we are hopeful that patients worldwide will soon be able to benefit from enhanced treatment options. Stay tuned!   To all of you, your families and loved ones, business partners and neighbors stay safe, healthy and count your blessings, for most of the time you will realize that you can easily focus on being a blessing to others. Finally, and most importantly: don’t stop looking for wonders! “The most wonderful thing about wonders is this: sometimes they really happen!” (G.K. Chesterton)   Season’s greetings and a happy New Year Frank Heideloff

The concept of personalized medicine has been explored for a while and it encompasses a variety of therapeutic concepts from highly selective antibody therapies to patient specific cell therapies. But how can this concept be applied to the challenges of end stage renal disease patients who depend on dialysis treatment? Find some answers in our most recent episode of our “3 questions” interview series featuring Crearene AG’s CEO Frank Heideloff and Frederic Palesch, co-founder of our collaboration partner Renephro. #endstagerenaldisease, #chronickidneydisease, #dialysis, #personalizedmedicine, #innovationindialysis, #creatineindialysis

The concept of personalized medicine has been explored for a while and it encompasses a variety of therapeutic concepts from highly selective antibody therapies to patient specific cell therapies. But how can this concept be applied to the challenges of end stage renal disease patients who depend on dialysis treatment? Find some answers in our most recent episode of our “3 questions” interview series featuring Crearene AG’s CEO Frank Heideloff and Frederic Palesch, co-founder of our collaboration partner Renephro. #endstagerenaldisease, #chronickidneydisease, #dialysis, #personalizedmedicine, #innovationindialysis, #creatineindialysis

For a long time, the team at Crearene AG has held the opinion that intra-dialytic creatine administration can replenish the depleted creatine levels of CKDpatients, resulting in a true improvement potential for physical and cognitive capabilities. And now we have the proof that replenishment is possible this way! Listen to Crearene AG’s CEO Frank Heideloff and our principal investigator Stephan Bakker from UMCG discussing the results of our recently completed clinical study. #chronickidneydisease, #hemodialysis, #creatine, #clincaltrials, #innovationindialysis, #creatineindialysis

Intradialytic Parenteral Nutrition, or IDPN for short, describes the simultaneous administration of essential nutrients during the dialysis process. But how should you administer supplementary creatine without endangering the patient’s life or altering the dialysis workflow? Listen to Sietske Doorenbos researcher at UMCG discussing with Crearene AG’s CEO Frank Heideloff how we addressed this challenge in our recent clinical trial. Spoiler alert - there is no more challenge! #intradialyticnutrition, #kidneydisease, #CKD, #dialysis, #clinicaltrials, #creatine, #innovationindialysis, #creatineindialysis

Creatine is the second most abundant small molecule in humans and serves as a universal energy buffer. Have you ever wondered how creatine can be manufactured synthetically in large quantities and with favorable cost of goods? In our latest episode of our “3 questions” interview series, Crearene AG’s CEO Frank Heideloff is discussing with Weichselbaumer Georg, Chief Sales Officer of Alzchem Group AG, how this can be achieved. You can also access the complete interview via Crearene AG’s homepage. #costofgoods, #chemicalmanufacturing, #creatine, #creapure, #creavitalis, #creatineindialysis, #innovationindialysis

Crearene and Renephro agree to collaborate on Innovative Treatment & Machine Combinations for the Global Dialysis Market Crearene AG, based in Frauenfeld, Switzerland, patent holder for innovative treatments in dialysis using creatine compounds and kits, who recently successfully completed a clinical study, and Renephro, based in Bielefeld, Germany, recent winner of an EXIST grant of the German ministry of economy and climate protection (BMWK), developing a patient-individualized dialysis pump, have agreed to collaborate on innovative, individualized treatment technologies bringing enhanced dialysis solutions to the global market. Dr. Frank Heideloff (CEO, Crearene AG) explains: “Today, there are more than 3.5 million dialysis patients globally who rely on regular hemodialysis treatment. There has been little to no innovation over the years regarding treatments improving the quality of life of dialysis patients. Our recently concluded clinical study has demonstrated that the chronic creatine depletion of dialysis patients can be overcome by adding creatine in the dialysis process. The patented know-how of Crearene, result of many years of research on the use of creatine, can serve as a catalyst here. We expect our technology in combination with the manufacturing innovation brought forward by Renephro to be an excellent base for this revolutionizing dialysis treatment.” Marvin Lohse (CTO and co-founder of Renephro) adds: “The recent improvements in dialysis machines have largely focused on controls and stability in terms of reproduceable, stable technical processes. But patient conditions vary significantly among chronic kidney disease patients and differ over time. Hence our innovative device aims to introduce patient-individualized treatment patterns into the dialysis market, lowering physical stress on e.g. the cardio-vascular system of dialysis patients plus reducing total system cost.” https://crearene.com https://renephro.com #creatine, #creatineindialysis, #dialysisinnovation, #renephro, #crearene,

Why can’t dialysis patients add creatine orally? A question that we at Crearene AG get asked a lot. In our latest series of “3 questions”, Möddel Michael, renown nephrologist and dialysis center practitioner, discusses with Crearene’s CEO Frank Heideloff, why fluid management is so important for dialysis patients. #fluidmanagement, #creatinesupplementation, #dialysis, #CKD, #Crearene, #innovationindialysis

When we talk about health, we first think about ailments like cardiovascular problems or oncology. Yet frequently unthought is the failure of the organ that tirelessly removes the unavoidable metabolic waste products of life from our body: the kidneys. The millions of dialysis patients worldwide are less fortunate in this regard and rely for survival on artificial kidneys, the dialysis machines. For these patients, fluid management plays a very important role in their daily planning. Watch Frank Heideloff and Uwe Riek discuss the importance of fluid balance in our latest episode of “three questions”. #kideneydisease, #dialysis, #chronicdisease, #endstagerenaldisease